



Sinclair Pharma plc

Appointment of new advisers

Godalming UK, 9 September, 2005: The Company today announces the appointment of Piper Jaffray Ltd. as nominated adviser and joint broker with immediate effect. In addition, the Company announces the appointment of Nomura International plc as joint broker, with immediate effect. Piper Jaffray Ltd. and Nomura International plc will act alongside Robert W. Baird who will remain in their existing role.

Enquiries:

Sinclair Pharma plc

Dr Michael Flynn, CEO

Tel: 01483 426 644

John Barrington-Carver (Media Enquiries)

Tel: 07831 655 630

Financial Dynamics

Ben Atwell / Lucy Briggs

Tel: 0207 831 3113

www.sinclairpharma.com

Notes to editors:

Sinclair Pharma plc based in Godalming in the UK, is quoted on the Alternative Investment Market (AIM) on the London Stock Exchange and has focused on the acquisition and development of niche patented pharmaceutical products in the fields of oral health, oncology support and dermatology, and bringing them to the international market place via out-licensing partners. The Company combines product evaluation, product development, regulatory and business development expertise to add value to its acquired and in-house developed products. A key element of the Sinclair business model is to minimise risk and exposure by avoiding involvement in lengthy R&D programmes and rapidly achieving global distribution through a network of marketing partners. The Company has already licensed its products for distribution in over 40 countries around the world.